Pregnant women have a higher risk of malaria compared to non-pregnant women. This
review provides an update on knowledge acquired since 2000 on P. falciparum and P. vivax …

Introduction: Chemotherapy of malaria has become a rapidly changing field. Less than two
decades ago, treatment regimens were increasingly bound to fail due to emerging drug …

The emergence and spread of parasite resistance to currently available antimalarials has
highlighted the importance of developing novel antimalarials. This scoping review provides …

Over the past 10 years, the available evidence on the treatment of malaria during pregnancy
has increased substantially. Owing to their relative ease of use, good sensitivity and …

Use of pharmacotherapy during pregnancy is common and increasing. Physiologic changes
during pregnancy may significantly alter the overall systemic drug exposure, necessitating …

Abstract Background The majority of Plasmodium falciparum malaria cases in Africa are
treated with the artemisinin combination therapies artemether-lumefantrine (AL) and …

Introduction: Malaria in pregnancy and postpartum cause maternal mortality and adverse
fetal outcomes. Efficacious and safe antimalarials are needed to treat and prevent such …

Half of all pregnancies at risk of malaria worldwide occur in the Asia–Pacific region, where
Plasmodium falciparum and Plasmodium vivax co-exist. Despite substantial reductions in …

Pregnancy alters the pharmacokinetic properties of many antimalarial compounds. The
objective of this study was to evaluate the pharmacokinetic properties of lumefantrine in …

Pregnancy alters the pharmacokinetic properties of many drugs used in the treatment of
malaria, usually resulting in lower drug exposures. This increases the risks of treatment …